1Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China
2Institute of Acupuncture and Moxibustion in Cancer Care, Beijing University of Chinese Medicine, Beijing, China
3Centre of Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
4China-Japan Friendship Hospital, Beijing, China
©2023 Jaseng Medical Foundation
This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Aged 18–75, no gender limitation.
Meet the LARS diagnostic criteria, LARS score ≥ 20.
KPS score ≥ 60, expected survival > 3 months, no staging and metastasis limitation.
Agreed to participate in the study and signed the informed consent.
With past medical history: other anorectal surgery or trauma, spinal cord, brain, and other nerve injuries which make patients unable to control defecation, serious complications, and anaphylactic reactions or adverse events occurred during acupuncture which make patients unable to tolerate acupuncture.
With complications: other anorectal diseases, anastomotic leakage, anastomotic bleeding, anastomotic stenosis, and intestinal perforation.
Receiving other acupuncture treatment.
With sacral malformation by any reason leading to inaccurate acupuncture point positioning.
Presence of other diseases: serious primary diseases of the cardiovascular, liver, kidney and hematopoietic systems and mental disorders.
Participating in other clinical studies.
With serious adverse events during treatment.
With aggravation and emergencies during treatment.
Failed to complete the treatment course and observation period specified in the study protocol for some reason.
Refuse to continue participating in the study or drop out of the study.
What was the main discomfort that you thought would bother you before receiving acupuncture treatment? What other approaches have you tried?
Why did you choose acupuncture?
What problems associated with LARS were most alleviated following treatment? After how many treatments was acupuncture beneficial? What was the biggest change in your life as a result of the treatment?
Did you have any discomfort from acupuncture treatment? Do you have any safety concerns?
Would you recommend acupuncture to other LARS patients? How would you introduce the treatment? Under what circumstances would you recommend acupuncture for LARS?
Do you have any suggestions or opinions on acupuncture as an intervention for LARS? What are the disadvantages of acupuncture treatment? What needs to be improved?
Conduct quantitative and qualitative analysis independently.
According to the latest LARS diagnostic criteria, LARS patients have at least one of the 8 symptoms and one of the 8 consequences [2]. “Symptoms” and “Consequences” can be considered as two dimensions of convergent parallel design, and the eight symptoms and eight outcomes can be compared in these two dimensions. If new dimensions and information are discovered in the qualitative interview, it can be added appropriately.
Generate information to be compared and present these comparisons.
Author Contributions
Conceptualization,funding acquisition, methodology, writing-original draft, writing - review & editing: MY. Conceptualization, methodology, writing-original draft, writing - review & editing: MY. Resources, investigation, methodology, writing - review & editing: LX and QLZ. Conceptualization, methodology, software, writing - review & editing: XL. Methodology, resources, writing - review & editing: LH. Investigation, writing-review & editing: YDB, LY, and MZ. Resources, writing-review & editing: LHZ and NYL. Conceptualization, methodology, resources, supervision, writing-review & editing: JPL and JCH.
Conflicts of Interest
The authors have no conflicts of interest to declare.
Funding
The Capital’s Funds for Health Improvement and Research (no.: CFH2022-4-7046).
Ethical Statement
This protocol has been approved by the Institutional Review Board of the Third School of Clinical Medicine, Beijing University of Chinese Medicine (no.: BZYSY-2022KYKTPJ-07-XZ01). The protocol was registered on ISRCTNregistry (no.: ISRCTN12537763). Registered on 16 August 2022, https://www.isrctn.com/ISRCTN12537763. Any revision will be updated to the mentioned website.
Year of publication [refs] | Method | Outcomes | N | No. original studies | Type of research |
---|---|---|---|---|---|
2018 [9–10] | Diet and drugs | No significant effect was observed after taking probiotics, 5-HT3 improves WEXNER score | 25 | 2 | Case series |
2014 [11] | Pelvic floor rehabilitation | Results without LARS score, improved Cleveland incontinence score and FACT-C score had different degrees of benefit | 321 | 5 | Systematic reviews of included cohort studies |
2020 [12] | Transanal irrigation | No significant difference in LARS scores at 12 months | 37 | 1 | RCT |
2018 [13] | Antegrade enema | 88% of patients treated did not need an ostomy in the long term | 25 | 1 | Case series |
2015 [14] | Sacral nerve stimulation | Symptom improvement in 74% of patients (ITT analysis) | 43 | 7 | Systematic reviews of included case series |
5-HT3 = 5-hydroxytryptamine receptor antagonist; WEXNER score = fecal incontinence severity score; LARS = low anterior resection syndrome; FACT-C = Quality of Life Scale for Patients with Colorectal cancer; ITT analysis = intentionality analysis (whether the treatment was eventually included in the assigned group for statistical analysis of efficacy); RCT = randomized controlled trials.
LARS = Low anterior resection syndrome; MSKCC BFI = The Memorial Sloan-Kettering Cancer Center Bowel Function Instrument; EQ-5D = European Quality of live Five Dimensions Questionnaire; EORTC-QLQ-C30 = The European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-Core 30.
Considering the ethical principles and patient compliance = only some participants with mild LARS (around 15 people) will be selected for the anorectal pressure test. Safety and adverse events will be local and systemic adverse events of the intervention. Hematuria and stool routine = liver and kidney function = and infection will be tested at baseline and after the intervention. After at least 2 weeks of treatment = about 20 patients who are willing to cooperate with the interview will be selected for semi-structured qualitative interview.
Year of publication [refs] | Method | Outcomes | N | No. original studies | Type of research |
---|---|---|---|---|---|
2018 [ |
Diet and drugs | No significant effect was observed after taking probiotics, 5-HT3 improves WEXNER score | 25 | 2 | Case series |
2014 [ |
Pelvic floor rehabilitation | Results without LARS score, improved Cleveland incontinence score and FACT-C score had different degrees of benefit | 321 | 5 | Systematic reviews of included cohort studies |
2020 [ |
Transanal irrigation | No significant difference in LARS scores at 12 months | 37 | 1 | RCT |
2018 [ |
Antegrade enema | 88% of patients treated did not need an ostomy in the long term | 25 | 1 | Case series |
2015 [ |
Sacral nerve stimulation | Symptom improvement in 74% of patients (ITT analysis) | 43 | 7 | Systematic reviews of included case series |
Baseline | Treatment Week 1–4 | Time following final treatment (mo) | ||||||
---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 1 | 3 | 6 | ||
Intervention | ● | ● | ● | ● | ||||
| ||||||||
LARS score | ● | ● | ● | ● | ● | ● | ● | ● |
| ||||||||
MSKCC BFI score | ● | ● | ● | ● | ● | |||
| ||||||||
Anorectal pressure test | ● | ● | ||||||
| ||||||||
EQ-5D score | ● | ● | ● | ● | ● | ● | ||
| ||||||||
EORTC-QLQ-C30 score | ● | ● | ||||||
| ||||||||
Safety and adverse events* | ● | ● | ● | ● | ● | |||
| ||||||||
Follow-ups | ● | ● | ● |
5-HT3 = 5-hydroxytryptamine receptor antagonist; WEXNER score = fecal incontinence severity score; LARS = low anterior resection syndrome; FACT-C = Quality of Life Scale for Patients with Colorectal cancer; ITT analysis = intentionality analysis (whether the treatment was eventually included in the assigned group for statistical analysis of efficacy); RCT = randomized controlled trials.
LARS = Low anterior resection syndrome; MSKCC BFI = The Memorial Sloan-Kettering Cancer Center Bowel Function Instrument; EQ-5D = European Quality of live Five Dimensions Questionnaire; EORTC-QLQ-C30 = The European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-Core 30. Considering the ethical principles and patient compliance = only some participants with mild LARS (around 15 people) will be selected for the anorectal pressure test. Safety and adverse events will be local and systemic adverse events of the intervention. Hematuria and stool routine = liver and kidney function = and infection will be tested at baseline and after the intervention. After at least 2 weeks of treatment = about 20 patients who are willing to cooperate with the interview will be selected for semi-structured qualitative interview.